These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21258806)

  • 1. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
    Seidel C; Fenner M; Merseburger AS; Reuter C; Ivanyi P; Länger F; Ganser A; Grünwald V
    World J Urol; 2011 Jun; 29(3):355-60. PubMed ID: 21258806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
    Stroup SP; Raheem OA; Palazzi KL; Liss MA; Mehrazin R; Kopp RP; Patel N; Cohen SA; Park SK; Patterson AL; Kane CJ; Millard F; Derweesh IH
    Urology; 2013 Apr; 81(4):805-11. PubMed ID: 23414694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.
    Grünwald V; Weikert S; Seidel C; Busch J; Johannsen A; Fenner M; Reuter C; Ganser A; Johannsen M
    Onkologie; 2011; 34(6):310-4. PubMed ID: 21625184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
    Albiges L; Oudard S; Negrier S; Caty A; Gravis G; Joly F; Duclos B; Geoffrois L; Rolland F; Guillot A; Laguerre B; Legouffe E; Kohser F; Dietrich PY; Theodore CA; Escudier B
    J Clin Oncol; 2012 Feb; 30(5):482-7. PubMed ID: 22231040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
    Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
    Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapy for Renal Cell Carcinoma.
    Joshi R; Rawal S
    JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
    Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
    Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
    N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
    Bex A; van der Veldt AA; Blank C; van den Eertwegh AJ; Boven E; Horenblas S; Haanen J
    World J Urol; 2009 Aug; 27(4):533-9. PubMed ID: 19145434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
    BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
    Park I; Park K; Park S; Ahn Y; Ahn JH; Choi HJ; Jeong IG; Song C; Hong JH; Kim CS; Ahn H; Lee JL
    Clin Genitourin Cancer; 2013 Sep; 11(3):276-82. PubMed ID: 23332873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 15. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
    Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
    Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
    Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
    Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
    Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R
    Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
    Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
    Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
    Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
    Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.